Piezo Therapeutics

Piezo Therapeutics, developed by Georgia Tech researchers, specializes in a groundbreaking drug delivery platform that integrates electric pulses and microneedles. This innovative approach aims to enhance the safety, affordability, and global accessibility of RNA and DNA medicines, including mRNA vaccines, immunotherapies, therapeutic proteins, and gene therapies. The company operates in the biotechnology sector, focusing on preventative and personalized medicine. Piezo Therapeutics serves pharmaceutical companies and research institutions looking to improve the delivery of nucleic acid-based therapies. The business model revolves around partnerships and collaborations to commercialize its technology, generating revenue through licensing agreements and service contracts. The team comprises experts with extensive backgrounds in pharmacology, drug development, and chemical engineering, ensuring a robust foundation for translating research into market-ready solutions.

Keywords: drug delivery, microneedles, electric pulses, RNA therapies, DNA therapies, mRNA vaccines, immunotherapies, gene therapies, biotechnology, personalized medicine.